Mirae Industry Invests 13 Billion in Cha Healthcare 'Full Cycle'

KOSPI-listed company Mirae Industry announced on the 28th that it will invest 13 billion KRW in the ‘Daishin-Y2HC New Technology Investment Association No. 1’ for the purpose of a full-cycle investment (investment - corporate value enhancement - profit realization) as its first large-scale investment in ‘CHA Healthcare,’ an affiliate of CHA Bio Group.

The ‘Daishin-Y2HC New Technology Investment Association No. 1’ is an investment association formed to invest equity in ‘CHA Healthcare,’ which aims for an IPO in 2025. The general partners (GP) managing the fund are Daishin Securities and one other company.

CHA Healthcare, a subsidiary of CHA Biotech, is a global healthcare company building a global healthcare platform based on the 60 years of medical expertise and know-how of CHA Hospital, with a medical network of 86 institutions across seven countries including the U.S., Australia, Singapore, and Japan. It generates profits by investing capital overseas and directly operating hospitals.

A representative example is the Hollywood CHA Hospital (CHA HPMC) in Los Angeles, U.S., acquired in 2004. Since then, CHA HPMC has established itself as a leading private general hospital in the LA area with 434 beds and over 500 specialized medical staff, treating approximately 14,000 inpatients annually and performing more than 5,000 surgeries per year. Currently, it is constructing a new hospital building with an annual area of 16,068㎡ (4,860 pyeong) at a cost of 400 million USD (approximately 457 billion KRW), aiming to become California’s top advanced general hospital.

In 2014, CHA Healthcare entered the Japanese cell therapy market and began operating the Total Cell Clinic (TCC). It is growing by providing immune cell therapy for cancer patients and stem cell therapy for diabetes patients. In 2017, it acquired shares in Singapore Medical Group (SMG), the largest hospital group in Southeast Asia, and expanded its business by opening 49 clinics in Singapore, Indonesia, and other locations.

In 2018, it entered the Australian infertility treatment market by acquiring City Fertility and FSWA, which operate infertility clinics in major cities. Based on the dispatch of CHA Hospital medical staff and advanced infertility treatment technology, the number of clinics increased from 7 to 21, continuing to grow as one of Australia’s top three infertility centers.

CHA Healthcare, which has established bio and healthcare affiliates and medical institutions locally in the U.S. and other countries and achieved significant results through direct entry, recorded sales of 648.5 billion KRW last year and expects stable sales growth in the future.

CHA Healthcare is planning to list on the domestic stock market in 2025 and is expected to attract market attention as Korea’s first model allowing domestic investors to invest in overseas hospitals.

Mirae Industry, which decided to invest 13 billion KRW in CHA Healthcare, recently expanded its portfolio for sustainable growth after being acquired by Nexton Bioscience and is undergoing restructuring to stabilize its existing business.

On the 13th, Mirae Industry signed a tripartite memorandum of understanding (MOU) in Hong Kong with Cheonho Investment Limited (DINHOR INVESTMENT LIMITED), a Hong Kong corporation owning lithium mines in Nigeria, and AVC CO., LIMITED, a company specializing in lithium distribution. They plan to officially start a new business related to lithium ore and announced that they will soon provide test samples of lithium ore to domestic demand sources.

Cheonho Investment Limited owns three lithium mines in Nigeria with an estimated reserve of about 5 million tons and a mining period of 25 years. Mining at one site began earlier this year. Mirae Industry signed a tripartite MOU to exclusively purchase up to 500,000 tons of lithium ore annually in Korea for a certain period through this agreement.

A Mirae Industry official stated, “Our company is reorganizing its internal organization to ensure continuous growth in its core semiconductor inspection equipment business and is promoting growth as a trusted semiconductor equipment company through compliance management and eradication of corruption. This investment is our first large-scale investment based on cooperation with affiliates and strategic decision-making, and we will show further growth of the company through corporate value enhancement.”

This content was produced with the assistance of AI translation services.